Jiangsu Apon Medical Technology Co Ltd Class A (300753) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Jiangsu Apon Medical Technology Co Ltd Class A ¥10.86, price ¥20.66, upside -47.4%, quality 48 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Jiangsu Apon Medical Technology Co Ltd Class A for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 4, 2026.
How to read this chart
60‑month range ¥8.48 – ¥43.19 · fair‑value band ¥7.17 – ¥13.61 · the ¥20.66 price screens above the ¥10.86 fair value. Dashed = 300-day average. As of Oct 4, 2026.
Follow Jiangsu Apon Medical Technology Co Ltd Class A in your weekly email
Every Wednesday you see whether Jiangsu Apon Medical Technology Co Ltd Class A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Jiangsu Apon Medical Technology Co., Ltd. engages in the research and development, production, and sale of medical devices in China.
Show more
Jiangsu Apon Medical Technology Co., Ltd. engages in the research and development, production, and sale of medical devices in China. The company's principal products include microcomputer injection pumps, disposable injection pumps, wireless analgesia management systems, and pulse oximeters, as well as medical devices, such as sensors in the field of pain management and nasal care sprayers. Jiangsu Apon Medical Technology Co., Ltd. was founded in 2001 and is headquartered in Nantong, China.
Stock analysis
Jiangsu Apon Medical Technology Co Ltd Class A (300753) currently trades at ¥20.66, while our model-based Fair Value estimate is ¥10.86, 47.4% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 92/100, which puts the evidence level at low.
Scenario range: ¥7.17 (bear) to ¥13.61 (bull), the price of ¥20.66 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Jiangsu Apon Medical Technology Co Ltd Class A reported revenue of 342M CNY in FY2025 versus 461M CNY in FY2021, a compound −7.2%/yr. Reported net income was −24.0M CNY in FY2025.
Key figures
Market cap 2.6B CNY (≈ $389M) · P/S ratio 7.85 · EPS (TTM) ¥−0.1200 · Dividend yield 0.4% · Net margin −7.0% · Return on equity −2.8% · Return on assets (EBIT) −0.5% · Operating margin −8.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 52% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −37% fair-value upside, at −47%, 300753 screens richer than that median.
Fair Value models
Bear ¥7.17Fair Value ¥10.86Bull ¥13.61
Price ¥20.66 · Upside -47.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
−15.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.0%
Start year 2020 (pandemic). Over 10 years: +8.3% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
25.6% (2020) → −7.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Jiangsu Apon Medical Technology Co Ltd Class A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 189 stocks
Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score48 · Below median
Fair Value upside−47.4% · Below median
Profitability
Return on assets−1.2% · Bottom 25%
Net margin (TTM)−4.4% · Bottom 25%
Operating margin (TTM)−8.7% · Bottom 25%
Growth and dividend
Revenue growth−14.7% · Bottom 25%
Dividend yield (TTM)0.4% · Bottom 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/B0.58× · Cheapest 25%
P/S (TTM)1.17× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 16
FUTURE (revenue growth)0· sector 38
PAST (return on equity)0· sector 28
HEALTH (low debt)0· sector 96
DIVIDEND (yield)8· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Jiangsu Apon Medical Technology Co Ltd Class A Fair Value". https://www.fairvalue-calculator.com/stock/300753
Frequently asked questions
Is Jiangsu Apon Medical Technology Co Ltd Class A (300753) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of ¥10.86 versus a price of ¥20.66, about −47% upside (overvalued).
What is the fair value of 300753?
Our model-based fair value for Jiangsu Apon Medical Technology Co Ltd Class A is ¥10.86 (as of Oct 4, 2026), built from audited fundamentals. The current price: ¥20.66.
What is the quality score of 300753?
Jiangsu Apon Medical Technology Co Ltd Class A has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
Our model-based price target is the fair value of ¥10.86 (as of Oct 4, 2026) from 1 valuation models. Cautious scenario ¥7.17, optimistic scenario ¥13.61. It is a calculation from audited fundamentals, not an analyst target.
What is the Jiangsu Apon Medical Technology Co Ltd Class A stock forecast for 2026?
Our models put fair value at ¥10.86, about −47% upside versus a price of ¥20.66 (overvalued). Cautious scenario ¥7.17, optimistic scenario ¥13.61. The calculation is refreshed regularly with new filings.
What is the revenue of Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
Jiangsu Apon Medical Technology Co Ltd Class A reported trailing-twelve-month revenue of about 332M CNY (latest available figure, as of Oct 4, 2026).
Does Jiangsu Apon Medical Technology Co Ltd Class A pay a dividend?
Jiangsu Apon Medical Technology Co Ltd Class A currently shows a dividend yield of about 0.39% relative to its recent price (as of Oct 4, 2026).
What is the intrinsic value of Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jiangsu Apon Medical Technology Co Ltd Class A it is ¥10.86 per share (as of Oct 4, 2026), against a price of ¥20.66. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Jiangsu Apon Medical Technology Co Ltd Class A stock overvalued or undervalued in 2026?
As of Oct 4, 2026, 300753 trades above its calculated fair value: price ¥20.66, fair value ¥10.86, a gap of about −47% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300753?
No. The price is what the market pays today (¥20.66); the fair value is what the company's own numbers justify (¥10.86). For Jiangsu Apon Medical Technology Co Ltd Class A the two are ¥9.80 per share apart. That gap is exactly why we show both numbers side by side.
How much is Jiangsu Apon Medical Technology Co Ltd Class A worth?
The market values Jiangsu Apon Medical Technology Co Ltd Class A at about 2.6B CNY (market capitalisation, as of Oct 4, 2026). Per share that is ¥20.66; our models calculate a fair value of ¥10.86 per share.
What do the bullish and bearish scenarios say about 300753?
Our models span a range for Jiangsu Apon Medical Technology Co Ltd Class A: cautious scenario ¥7.17, base ¥10.86, optimistic ¥13.61 per share (as of Oct 4, 2026, price ¥20.66). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
Balance-sheet figures for Jiangsu Apon Medical Technology Co Ltd Class A (as of Oct 4, 2026): return on equity −2.8%. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is 300753 from its 52-week high?
Jiangsu Apon Medical Technology Co Ltd Class A trades at ¥20.66, about 52% below its 52-week high of ¥43.19 and 14% above the low of ¥18.16 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of ¥10.86 is for.
Which stocks are comparable to Jiangsu Apon Medical Technology Co Ltd Class A?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jiangsu Apon Medical Technology Co Ltd Class A stock attractive at the current price?
The data as of Oct 4, 2026: price ¥20.66, calculated fair value ¥10.86 (−47%), Quality Score 48/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300753 calculated?
We run Jiangsu Apon Medical Technology Co Ltd Class A through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥10.86, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Jiangsu Apon Medical Technology Co Ltd Class A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
The closing price on Sep 30, 2026 was ¥20.66. Our model-based fair value is ¥10.86, about −47% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jiangsu Apon Medical Technology Co Ltd Class A right now?
The price sits above even our optimistic bull case (¥13.61). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (¥7.17 to ¥13.61) leaves room in how you read the outcome.
Where does the earnings growth of Jiangsu Apon Medical Technology Co Ltd Class A (300753) come from?
Earnings per share at Jiangsu Apon Medical Technology Co Ltd Class A grew −21.9 % a year from 2014 to 2024. Broken into its drivers: revenue per share +0.4 %, EBIT margin −16.4 %, tax rate −4.7 %, residual (interest, one-offs) −2.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Jiangsu Apon Medical Technology Co Ltd Class A
How large is the market capitalisation of Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
The market capitalisation of Jiangsu Apon Medical Technology Co Ltd Class A is 2.6B CNY (≈ $389M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
The price-to-sales ratio of Jiangsu Apon Medical Technology Co Ltd Class A is 7.85 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
Earnings per share at Jiangsu Apon Medical Technology Co Ltd Class A are ¥−0.1200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
The dividend yield of Jiangsu Apon Medical Technology Co Ltd Class A is 0.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
The net margin of Jiangsu Apon Medical Technology Co Ltd Class A is −7.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
The return on equity (ROE) of Jiangsu Apon Medical Technology Co Ltd Class A is −2.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
On an EBIT basis the return on assets of Jiangsu Apon Medical Technology Co Ltd Class A is −0.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
The operating margin of Jiangsu Apon Medical Technology Co Ltd Class A is −8.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
Revenue at Jiangsu Apon Medical Technology Co Ltd Class A is growing −14.7% versus a year earlier (3y avg +1.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Jiangsu Apon Medical Technology Co Ltd Class A (300753)?
Earnings per share at Jiangsu Apon Medical Technology Co Ltd Class A are growing +372% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Jiangsu Apon Medical Technology Co Ltd Class A (300753) generate?
The free cash flow of Jiangsu Apon Medical Technology Co Ltd Class A is −6.1M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Jiangsu Apon Medical Technology Co Ltd Class A (300753) hold?
Jiangsu Apon Medical Technology Co Ltd Class A holds more cash than debt, 125M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Jiangsu Apon Medical Technology Co Ltd Class A in the live analysis
One click puts Jiangsu Apon Medical Technology Co Ltd Class A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
